Musashi Fukuda
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Journal: Clinical trials (London, England)
Published: July 17, 2023
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Journal: Modern rheumatology
Published: December 02, 2021
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Journal: Modern rheumatology
Published: May 21, 2021
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: February 24, 2021
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Journal: Modern rheumatology
Published: October 14, 2020
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Journal: Investigational new drugs
Published: March 05, 2019
Meta-analysis of randomized clinical trials in the era of individual patient data sharing.
Journal: International journal of clinical oncology
Published: November 09, 2017
The Number of Events per Confounder for Valid Estimation of Risk Difference Using Modified Least-Squares Regression.
Journal: American journal of epidemiology
Published: September 04, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026